Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2019-05-29 AGM Information
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Minutes from Annual General Meeting 2019
AGM Information Classification · 100% confidence The document text is titled 'PROTOKOLL FRA ORDINÆR GENERALFORSAMLING' which translates to 'MINUTES FROM ORDINARY GENERAL MEETING'. The content details the proceedings, resolutions passed (including approval of the 2018 annual accounts and election of the board), and attendance records of a meeting held on May 29, 2019. This clearly identifies the document as the official minutes or record of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2019-05-29 Norwegian
PCI Biotech: Minutes from Annual General Meeting 2019
AGM Information Classification · 99% confidence The document title explicitly states 'Minutes from Annual General Meeting 2019'. The text confirms that the Annual General Meeting took place and details the resulting board composition. Although it mentions the 'complete minutes... are attached to this release', the core content provided is the summary/minutes of the AGM itself, including resolutions and board changes. This strongly aligns with the 'AGM Information' category, which covers presentations and materials shared during the AGM. Since the document *is* the minutes (a key material), AGM-R is the most appropriate classification over RPA or RNS.
2019-05-29 English
PCI Biotech: Disclosure of voting rights for Chairman of the Board
AGM Information Classification · 98% confidence The document explicitly mentions 'chairman, Hans Peter Bøhn' and details his shareholding and powers of attorney specifically for the 'annual general meeting of the Company on 29 May 2019'. This content directly relates to the setup, participants, and voting structure surrounding an AGM. Although it contains director information, the context is strictly tied to the upcoming AGM proceedings. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length is short, but it is the primary information itself, not an announcement of a separate AGM document.
2019-05-28 English
PCI Biotech: Disclosure of voting rights for Chairman of the Board
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is a 'Disclosure of voting rights for Chairman of the Board' and details the number of shares held and represented by proxy by the Chairman for the upcoming Annual General Meeting (AGM). This directly relates to insider transactions or holdings of key personnel, specifically concerning voting power at a shareholder meeting. Among the provided definitions, 'Director's Dealing' (DIRS) covers personal share transactions by directors and executives. Although this is about voting rights representation rather than a sale/purchase, it falls under the scope of executive/director financial/holding disclosures more closely than other options. However, since the context is specifically about the Chairman's voting rights representation for the AGM, and there is no specific code for 'Voting Rights Disclosure by Director', DIRS (Director's Dealing) is the closest fit for executive holding disclosure. If the document were about the *results* of the vote, DVA would apply, but this is a pre-meeting disclosure of representation power.
2019-05-28 English
PCI Biotech: First patient enrolled in the fimaChem pivotal RELEASE study
Regulatory Filings Classification · 100% confidence The document announces a significant clinical milestone: the first patient enrollment in the pivotal 'RELEASE study' for the drug fimaChem, targeting inoperable bile duct cancer. It details the study design (randomized, endpoints like PFS/OS), regulatory interactions (EMA/FDA), expected timelines, and provides background on the disease and technology. This content is characteristic of a press release detailing clinical trial progress and strategic updates, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive Interim Report (IR). Since it is a specific announcement about clinical development progress and not a general regulatory filing (RNS) or a presentation (IP), it best fits the category for updates on financing, capital structure, or significant corporate/clinical developments that don't fit other specific codes. However, given the options, this is a major corporate update regarding clinical progress. It is not a management report (MDA) which focuses on financial results, nor is it a capital/financing update (CAP). It is a specific announcement of a clinical event. In the context of the provided definitions, this type of announcement—a press release detailing clinical trial progress and milestones—is often classified under 'Regulatory Filings' (RNS) if no better fit exists, or sometimes grouped with Investor Presentations (IP) if it were a slide deck. Since it is a news announcement about a clinical trial kick-off, and it is not a formal financial report, the most appropriate general category for significant, non-financial, non-management-change announcements is RNS, as it is a regulatory-relevant update for investors.
2019-05-23 English
PCI Biotech: Notice of Annual General Meeting 2019
AGM Information Classification · 98% confidence The document explicitly invites shareholders to attend the 'Annual General Meeting 2019' (AGM) on May 29th. It mentions that the notice, including the executive remuneration statement and the Nomination Committee's recommendation, is attached. Since the core purpose of this short document is to announce the meeting details and provide access to the associated materials (Notice, Remuneration Statement, Nomination Committee Proposal), it falls under the category of AGM Information. Although it mentions remuneration (DEF 14A) and committee proposals, the primary context is the meeting itself. Given the options, AGM-R (AGM Information) is the most appropriate classification.
2019-05-08 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.